Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | PPP5C | P53041 | 2/20 | 0.46 |
| ▸ | TFPI2 | P48307 | 2/20 | 0.46 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.46 |
| ▸ | NPY4R | P50391 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | PPM1B | O75688 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9880176 | 0.87 | TSHR (0.42) | TSHRTFPI2ATMLMNASMN1; SMN2 | |
| SCHEMBL19177682 | 0.84 | TSHR (0.40) | TSHRTFPI2ATMSMN1; SMN2PPM1B | |
| SCHEMBL9880146 | 0.83 | TFPI2 (0.60) | TSHRPPP5CTFPI2PPP2CANPY4R | |
| SCHEMBL16731268 | 0.82 | PPP5C (0.41) | TSHRPPP5CTFPI2PPP2CANPY4R | |
| SCHEMBL9880162 | 0.82 | PPP5C (0.48) | TSHRPPP5CTFPI2PPP2CANPY4R | |
| SCHEMBL9880171 | 0.80 | PPP5C (0.39) | TSHRPPP5CTFPI2PPP2CANPY4R | |
| SCHEMBL9881386 | 0.80 | PPP5C (0.49) | TSHRPPP5CTFPI2PPP2CANPY4R | |
| SCHEMBL9696402 | 0.79 | PPM1B (0.44) | TSHRTDP1PPM1BPTPN1PPP1CC | |
| SCHEMBL2005428 | 0.79 | PPM1B (0.44) | TSHRTDP1PPM1BPTPN1PPP1CC | |
| SCHEMBL2002666 | 0.79 | PPM1B (0.44) | TSHRTDP1PPM1BPTPN1PPP1CC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210275521-A1 | OXABICYCLOHEPTANES FOR TREATMENT OF SECONDARY ACUTE MYELOID LEUKEMIA | LIXTE BIOTECHNOLOGY, INC. | 2021-09-09 | — | — | US | disclosed |
| EP-3258930-B1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DEPRESSIVE AND STRESS DISORDERS | LIXTE BIOTECHNOLOGY INC (US) | 2020-12-09 | — | — | EP | disclosed |
| US-20200179375-A1 | FORMULATIONS OF OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES | LIXTE BIOTECHNOLOGY, INC. | 2020-06-11 | — | — | US | disclosed |
| US-10668062-B2 | Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes | LIXTE BIOTECHNOLOGY, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-10434100-B2 | Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes | LIXTE BIOTECHNOLOGY, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-10413541-B2 | Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders | LIXTE BIOTECHNOLOGY, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-10399993-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| WO-2019113155-A1 | OXABICYCLOHEPTANES FOR TREATMENT OF SECONDARY ACUTE MYELOID LEUKEMIA | LIXTE BIOTECHNOLOGY, INC. (US) | 2019-06-13 | — | — | WO | disclosed |
| US-20190167671-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES | LIXTE BIOTECHNOLOGY, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20190046525-A1 | PROTEIN PHOSPHATASE 2A INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROMES | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-02-14 | — | — | US | disclosed |
| US-20110287537-A1 | NEUROPROTECTIVE AGENTS FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | LIXTE BIOTECHNOLOGY, INC. | 2011-11-24 | — | — | US | disclosed |
| US-8058268-B2 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | LIXTE BIOTECHNOLOGY, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-7998957-B2 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998957-B2 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| WO-2010014220-A1 | NEUROPROTECTIVE AGENTS FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | LIXTE BIOTECHNOLOGY, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20100029640-A1 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | LIXTE BIOTECHNOLOGY, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029640-A1 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | LIXTE BIOTECHNOLOGY, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20090036309-A1 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090036309-A1 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. | 2009-02-05 | — | — | US | disclosed |
| WO-2008097561-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHOLOGY HOLDINGS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029640-A1 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | SNCA, NLN, HTT | TSHR 2429/4885PPP5C 2709/4885TFPI2 4324/4885 |
| US-20200179375-A1 | FORMULATIONS OF OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES | PPP2CA, PPP2R2A, PPM1A | TSHR 3083/4885PPP5C 9/4885TFPI2 4454/4885 |
| US-10413541-B2 | Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders | HSD17B11, HSD17B1, CRH | TSHR 845/4885PPP5C 2219/4885TFPI2 4289/4885 |
| US-20190167671-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES | PPP2CA, PPP3CA, PPP6C | TSHR 836/4885PPP5C 12/4885TFPI2 3732/4885 |
| US-20190046525-A1 | PROTEIN PHOSPHATASE 2A INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROMES | PPP2CA, PPP2R2A, PPM1A | TSHR 3796/4885PPP5C 8/4885TFPI2 1195/4885 |
| US-20210275521-A1 | OXABICYCLOHEPTANES FOR TREATMENT OF SECONDARY ACUTE MYELOID LEUKEMIA | MCL1, MYD88, SAMHD1 | TSHR 3167/4885PPP5C 1464/4885TFPI2 4378/4885 |
| US-20090036309-A1 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | HCCS, VHL, OXA1L | TSHR 2338/4885PPP5C 2860/4885TFPI2 4843/4885 |
| US-10399993-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | HCCS, OXA1L, OTC | TSHR 1659/4885PPP5C 3037/4885TFPI2 4858/4885 |
| US-10434100-B2 | Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes | PPP2CA, PPP2R2A, PPM1A | TSHR 3796/4885PPP5C 8/4885TFPI2 1195/4885 |
| US-10668062-B2 | Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes | PPP2CA, PPP3CA, PPP6C | TSHR 836/4885PPP5C 12/4885TFPI2 3732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.